In patients with PsO treated with risankizumab or guselkumab, early response was a significant factor in maintaining stable long-term response. Therefore, early response is a clinically relevant factor to consider when optimizing individual therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Akdoğan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: